



**Cancer Endorsement Maintenance Phase 2  
Breast Measures Workgroup 2  
Thursday, May 10, 2012  
4:00 pm ET**

**Please use the following information to access the conference call line:**

**Dial-in Number:** 1- 888- 523-1227

**Conference ID:** 4266189

**Event Title:** Cancer SC Phase 2 - Breast Measures Workgroup 2

**Webinar:** Register at <http://www.MyEventPartner.com/NQForum124>

Please note that the registration link will be activated 15 minutes prior to the meeting.

**AGENDA**

- 4:00 pm      **Welcome and Introductions**  
*Angela Franklin, JD Senior Director*  
*Lindsey Tighe, MS, Project Manager*  
*Adeela Khan, MPH, Project Analyst*
- 4:05 pm      **Workgroup Review of Breast Measures**
- 1857: Trastuzumab not administered to patients with AJCC stage I (T1c) – III, human epidermal growth factor receptor 2 (HER2) positive breast cancer (ASCO)
  - 1858: Trastuzumab administered to patients with AJCC stage I (T1c) – III, human epidermal growth factor receptor 2 (HER2) positive breast cancer (ASCO)
  - 1878: Human epidermal growth factor receptor 2 (HER2) testing in breast cancer (ASCO)
  - 1855: Quantitative HER2 evaluation by IHC uses the system recommended by the ASCO/CAP guidelines (ASCO; CAP)
  - 0387: Oncology: Hormonal Therapy for Stage IC Through IIIC, ER/PR Positive Breast Cancer (AMA-PCPI)
  - 0391: Breast Cancer Resection Pathology Reporting- pT category (primary tumor) and pN category (regional lymph nodes) with histologic grade (AMA-PCPI)
- 5:25 pm      **Next Steps**
- 5:30 pm      **Adjourn**